The filing is a presentation refresh, not a new operating announcement. Item 7.01 only furnishes an updated investor deck covering the three and six months ended June 30, 2026; it does not introduce quarterly guidance, a new transaction, or a complete GAAP earnings release. With no clean consensus comparison in the filing, there is no substantiated beat-or-miss call.
| Metric | Latest figure | Context |
|---|---|---|
| Owned/managed outpatient locations | 796 in 45 states | As of June 30, 2026 (USPH At a Glance) |
| Trailing revenue | $812 million | TTM through June 30, 2026 (USPH At a Glance) |
| Trailing adjusted EBITDA | $96 million | TTM through June 30, 2026; non-GAAP (USPH At a Glance) |
| Year-over-year revenue growth | 8% | Six months ended June 30, 2026 (USPH At a Glance) |
| Owned clinics added | 52 | Added from August 1, 2025 through July 31, 2026 (New Clinics Since August 1, 2025) |
| Second-quarter share repurchase | $19.2 million | 306,256 shares repurchased in Q2 2026 (Strong Balance Sheet and Capital Allocation Strategy) |
| Credit facility | $450 million | Increased from $325 million in April 2026; maturity April 14, 2031 (Strong Balance Sheet and Capital Allocation Strategy) |
| Industrial injury prevention revenue | $120.3 million TTM | YTD revenue up 10.4%; gross profit up 15.6%; gross margin 20.4% (Industrial Injury Prevention) |
The useful information is confirmation of execution, not surprise. The deck shows continued expansion—52 owned clinics added, 796 total owned or managed locations, 8% year-over-year revenue growth, and a $19.2 million Q2 repurchase—but these are descriptive operating updates rather than newly announced catalysts. The acquisition-led growth model and $450 million credit facility were already part of the company’s stated strategy (New Clinics Since August 1, 2025; Strong Balance Sheet and Capital Allocation Strategy).
The strongest incremental detail is capital allocation, but it still does not change the scorecard. Repurchasing 306,256 shares for $19.2 million and maintaining a $1.84 annual dividend show continued shareholder returns, while the enlarged facility preserves room for acquisitions (Strong Balance Sheet and Capital Allocation Strategy; USPH At a Glance). The filing does not say whether repurchases were accelerated, whether acquisition activity is changing, or whether leverage targets have moved.
The deck has a credibility blemish: one balance-sheet reference is visibly stale. The capital-allocation slide still includes June 30, 2024 cash and term-loan figures alongside June 30, 2026 information, making that section harder to interpret and weakening its usefulness as a current financial snapshot (Strong Balance Sheet and Capital Allocation Strategy). Net: the presentation reinforces the existing growth narrative, but adds no clearly unexpected information versus what investors likely already knew.
Read the original 8-K on SEC EDGAR ↗